Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
27 nov. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO and TOKYO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,...
FibroGen to Present at Upcoming Investor Conferences
06 nov. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen Reports Third Quarter 2020 Financial Results
05 nov. 2020 16h01 HE
|
FibroGen, Inc
- Strong Third Quarter China Roxadustat Net Sales of $22.7 Million -- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN FRANCISCO, Nov. 05, 2020 (GLOBE NEWSWIRE) --...
FibroGen to Report Third Quarter 2020 Financial Results
29 oct. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen will...
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
22 oct. 2020 10h08 HE
|
FibroGen, Inc
In non-dialysis and dialysis-dependent CKD patients, Major Adverse Cardiovascular Event (MACE) and MACE+ incidence rates were lowest when patients achieved hemoglobin levels ≥ 10 g/dL Two analyses of...
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
14 oct. 2020 07h00 HE
|
FibroGen, Inc
Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease (CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk...
FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
08 sept. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where...
FibroGen to Present at Upcoming Investor Conferences
01 sept. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
11 août 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab...
FibroGen Reports Second Quarter 2020 Financial Results
06 août 2020 16h02 HE
|
FibroGen, Inc
- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) --...